(Total Views: 672)
Posted On: 06/05/2024 4:19:20 PM
Post# of 155844
Quote:
Their drugable pathway involves MEK inhibition which is downregulated by Leronlimab per OHM…interesting to note that direct approach’s to inhibition seem to be associated with significant side effects.
Another example of a very high level of downregulation (via MEK inhibitors) inducing bad side effects vs. leronlimab downregulating overexpression to a more normal level by allowing other CCR receptor activity to continue.
(16)
(0)
